相关产品推荐更多 >

Vitamin D Binding Protein (Gc) Antibody/Vitamin D Binding Protein (Gc) Antibody/Vitamin D Binding Protein (Gc) Antibody
询价
OsChl21 Antibody/OsChl21 Antibody/OsChl21 Antibody
询价
Guanine Nucleotide Binding Protein Like Protein 1 (GNL1) Antibody (FITC)/Guanine Nucleotide Binding Protein Like Protein 1 (GNL1) Antibody (FITC)/Guanine Nucleotide Binding Protein Like Protein 1 (GNL1) Antibody (FITC)
询价
Hemojuvelin Antibody/Hemojuvelin Antibody/Hemojuvelin Antibody
询价
Procollagen III N-Terminal Propeptide (PIIINP) Antibody (Biotin)/Procollagen III N-Terminal Propeptide (PIIINP) Antibody (Biotin)/Procollagen III N-Terminal Propeptide (PIIINP) Antibody (Biotin)
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
Anti-PD-L2 antibody (<strong>4063</strong>) was raised against a peptide corresponding to 16 amino acids near the center of human PD-L2. <br> The immunogen is located within amino acids 140-190 of PD-L2.
- 保存条件:
stored at 4℃ for three months and -20℃, stable for up to one year
- 保质期:
1年
- 级别:
科研级别
- 库存:
100
- 供应商:
艾美捷科技
- 宿主:
兔
- 应用范围:
E, WB, IHC-P, IF
- 抗体英文名:
PD-L2 Antibody
- 抗体名:
PD-L2 Antibody
- 规格:
0.02mg
PD-L2 抗体,PD-L2 Antibody,PD-L2 抗体,PD-L2 Antibody
产品名称:PD-L2 抗体-PD-L2 Antibody
产品货号:PSI-4063-0.02mg
产品规格:0.02mg
背景资料:PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.
保存建议:PD-L2 抗体-PD-L2 Antibody stored at 4℃ for three months and -20℃, stable for up to one year
应用类型:E, WB, IHC-P, IF
点击:PD-L2 抗体-PD-L2 Antibody查看更详细产品说明,更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论,请点击查看艾美捷特色产品中心。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验上期带大家了解如今大热的 PD-L1免疫疗法,本期文章会对 PD-1 诊断抗体进行详细的分析。PD-1/PD-L1 单克隆抗体药备受瞩目,是目前临床上研究和应用最广泛的免疫检查点抑制剂之一,阻断 PD-1 与 PD-L1 的结合,使 T 细胞恢复肿瘤杀伤活性,在多种肿瘤治疗过程中显示出卓越的疗效[1]。目前 FDA 批准了 2 款 PD-1 抑制剂(Opdivo 和 Keytruda)和 3 款 PD-L1 抑制剂(Tecentriq、Imfinzi、Bavencio)上市。同时,也分别批准
了 B7 家族的第三个成员 B7-H1(即日后的 PD-L1)[2]。2000 年,Tasuku Honjo 教授等人证明了 PD-L1 能与 PD-1 结合,进而抑制 T 细胞的增殖与细胞因子的分泌,负调控淋巴细胞的激活,从此,B7-H1 被正式命名为 PD-L1(陈列平教授则继续使用「B7-H1」命名)[3]。2003年,陈列平教授第一次成功地使用 PD-L1 封闭抗体联合 T 细胞回输技术治愈了约 60% 的头颈癌小鼠[4]。2014 年 12 月,首个应用于肿瘤治疗的抗 PD-1 抗体
宽度:562 px高度:343 px维持原图长宽比:确认自 2011 年第一个免疫检验点 CTLA4 抑制剂伊匹单抗(Ipilimumab)获批上市以来,肿瘤免疫疗法越来越受到重视。特别是近几年陆续获批 PD1/PD-L1 单抗药物在临床治疗中的不断突破,肿瘤免疫治疗已从 1.0 时代进入 2.0 时代。免疫疗法适应症也在不断拓展,从黑色素瘤逐渐延伸到非小细胞肺癌、膀胱癌、头颈癌霍奇金淋巴瘤等癌症的治疗。针对 PD1/PD-L1 免疫检验点的单抗药物无疑是肿瘤免疫治疗中当之无愧的明星,其中 O
技术资料暂无技术资料 索取技术资料






